Overview

  • Product nameAnti-Ras antibody [EP1125Y]See all Ras primary antibodies ...
  • Description
    Rabbit monoclonal [EP1125Y] to Ras
  • Specificityab52939 is predicted to react with H-Ras, N-Ras and K-Ras.
  • Tested applicationsWB, IP, Flow Cytmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    A synthetic peptide corresponding to residues near the N-terminal region of human Ras.

  • Positive control
    • C6 cell lysate and permeabilized PC-12 cells.
  • General notes

    Produced under U.S. Patent No. 5,675,063.

    This product is available conjugated to DyLight® 488 see ab139859.

Applications

Our Abpromise guarantee covers the use of ab52939 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/10000 - 1/50000. Detects a band of approximately 18 kDa (predicted molecular weight: 18 kDa).
IP 1/30.
Flow Cyt 1/100.
  • Application notesIs unsuitable for ICC or IHC-P.
  • Target

    • FunctionRas proteins bind GDP/GTP and possess intrinsic GTPase activity.
    • Involvement in diseaseDefects in HRAS are the cause of faciocutaneoskeletal syndrome (FCSS) [MIM:218040]. A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities.
      Defects in HRAS are the cause of congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]. CMEMS is a variant of Costello syndrome.
      Defects in HRAS may be a cause of susceptibility to Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]. Hurthle cell thyroid carcinoma accounts for approximately 3% of all thyroid cancers. Although they are classified as variants of follicular neoplasms, they are more often multifocal and somewhat more aggressive and are less likely to take up iodine than are other follicular neoplasms.
      Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors.
      Defects in HRAS are a cause of susceptibility to bladder cancer (BLC) [MIM:109800]. A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.
      Note=Defects in HRAS are the cause of oral squamous cell carcinoma (OSCC).
    • Sequence similaritiesBelongs to the small GTPase superfamily. Ras family.
    • Post-translational
      modifications
      Palmitoylated by the ZDHHC9-GOLGA7 complex. A continuous cycle of de- and re-palmitoylation regulates rapid exchange between plasma membrane and Golgi.
      S-nitrosylated; critical for redox regulation. Important for stimulating guanine nucleotide exchange. No structural perturbation on nitrosylation.
    • Cellular localizationCell membrane. Golgi apparatus membrane. The active GTP-bound form is localized most strongly to membranes than the inactive GDP-bound form (By similarity). Shuttles between the plasma membrane and the Golgi apparatus.
    • Information by UniProt
    • Database links
    • Alternative names
      • c bas/has antibody
      • c H ras antibody
      • c has/bas p21 protein antibody
      • C K RAS antibody
      • c K ras2 protein antibody
      • c Ki ras antibody
      • c Kirsten ras protein antibody
      • c ras Ki 2 protein antibody
      • C-BAS/HAS antibody
      • c-H-ras antibody
      • C-HA-RAS1 antibody
      • Cellular c Ki ras2 proto oncogene antibody
      • CTLO antibody
      • G1III6 N ras antibody
      • GTPase HRas antibody
      • GTPase KRas antibody
      • GTPase NRas antibody
      • H Ras 1 antibody
      • H RasIDX antibody
      • H-Ras-1 antibody
      • H-RASIDX antibody
      • Ha Ras antibody
      • Ha-Ras antibody
      • HAMSV antibody
      • HRAS 1 antibody
      • HRAS antibody
      • HRAS1 antibody
      • K Ras 2 antibody
      • K ras antibody
      • K ras p21 protein antibody
      • K RAS2A antibody
      • K RAS2B antibody
      • K RAS4A antibody
      • K RAS4B antibody
      • K-RAS antibody
      • KI RAS antibody
      • Kirsten rat sarcoma 2 viral (v Ki ras2) oncogene homolog antibody
      • KRAS 1 antibody
      • KRAS 2 antibody
      • KRAS antibody
      • KRAS1 antibody
      • KRAS2 antibody
      • N ras antibody
      • N ras oncogene antibody
      • N-RAS antibody
      • N-terminally processed antibody
      • Neuroblastoma RAS viral (v ras) oncogene homolog antibody
      • NRAS 1 antibody
      • NRAS antibody
      • NRAS1 antibody
      • NS3 antibody
      • Oncogene KRAS2 antibody
      • p21 protein antibody
      • p21ras antibody
      • PR310 c K ras oncogene antibody
      • RASH 1 antibody
      • RASH_HUMAN antibody
      • RASH1 antibody
      • RASK 2 antibody
      • RASK2 antibody
      • Transforming protein N Ras antibody
      • Transforming protein p21 antibody
      • v Ha ras Harvey rat sarcoma viral oncogene homolog antibody
      • v Ki ras2 Kirsten rat sarcoma 2 viral oncogene homolog antibody
      • v Ki ras2 Kirsten rat sarcoma viral oncogene homolog antibody
      • v ras neuroblastoma RAS viral oncogene homolog antibody
      see all

    Anti-Ras antibody [EP1125Y] images

    • Anti-Ras antibody [EP1125Y] (ab52939) at 1/500000 dilution + C6 cell lysate at 10 µg/ml

      Secondary
      goat anti-rabbit HRP at 1/2000 dilution

      Predicted band size : 18 kDa
      Observed band size : 18 kDa
    • ab52939 at 1/100 dilution staining Ras in permeabilized PC-12 cells by flow cytometry (red). Rabbit IgG negative control (green).
    • Anti-Ras antibody [EP1125Y] (ab52939) at 1/500 dilution + Human Ras full length protein (ab56526) at 0.01 µg

      Secondary
      Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (ab97080) at 1/5000 dilution
      developed using the ECL technique

      Performed under reducing conditions.

      Exposure time : 1 minute

    References for Anti-Ras antibody [EP1125Y] (ab52939)

    This product has been referenced in:
    • Lee HW  et al. Real-time single-molecule co-immunoprecipitation analyses reveal cancer-specific Ras signalling dynamics. Nat Commun 4:1505 (2013). WB ; Human . Read more (PubMed: 23422673) »
    • Jiang MC  et al. CSE1L modulates Ras-induced cancer cell invasion: correlation of K-Ras mutation and CSE1L expression in colorectal cancer progression. Am J Surg 206:418-27 (2013). WB ; Human . Read more (PubMed: 23806821) »

    See all 5 Publications for this product

    Product Wall

    Thank you for kindly confirming these details. I am sorry these antibodies have not worked for this customer.

    As requested, we are pleased to arrange the alternative free of charge replacements. I can confirm that 1 vial of ab87980 and 1 via...

    Read More

    Thank you for taking the time to complete our questionnaire and contact us. I am sorry to hear the customer hashad difficulty obtaining satisfactory results from the free of charge replacement vials.

    The details you have kindly provided will...

    Read More
    Abcam guarantees this product to work in the species/application used in this Abreview.
    Application Western blot
    Sample Human Cell lysate - whole cell (A549)
    Loading amount 50 µg
    Specification A549
    Gel Running Conditions Reduced Denaturing (10% SDS-PAGE)
    Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
    Username

    Abcam user community

    Verified customer

    Submitted Sep 17 2010

    Thank you for your enquiry. I have obtained some further information on the flow cytometry protocol used to test this antibody. 2% paraformaldehyde was used for fixation: Solutions and Reagents: 1. 1X PBS 2. Blocking buffer 0.5% BSA in 1X PBS ...

    Read More

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"